• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Anavex Life Sciences Corp.

    4/9/21 5:06:46 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AVXL alert in real time by email
    S-8 1 e2594_s8.htm
     
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    __________________

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    __________________

    ANAVEX LIFE SCIENCES CORP.

    (Exact name of registrant as specified in its charter)

    Nevada

    98-0608404

    (State or other jurisdiction of (IRS Employer
    incorporation or organization) Identification Number)

    51 West 52nd Street, 7th Floor
    New York, NY 10019-6163
    Telephone: 1-844-689-3939
    (Address and Telephone Number of Principal Executive Offices)

    Christopher Missling, PhD
    Chief Executive Officer
    51 West 52nd Street, 7th Floor
    New York, NY 10019-6163
    Telephone: 1-844-689-3939
    (Name, Address and Telephone Number of Agent for Service)

    __________________

    Anavex Life Sciences Corp. 2007 Stock Option Plan

    Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan

    (Full Title of Plans)

    Copies to:

    Clayton E. Parker, Esq.
    John C. Scarborough, Jr., Esq.

    K&L Gates LLP
    200 South Biscayne Boulevard, Suite 3900
    Miami, Florida 33131-2399
    Telephone: (305) 539-3300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an "emerging growth company". See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ¨ Smaller reporting company x
    Non-accelerated filer x Emerging growth company ¨
    Accelerated filer ¨    

     

    (Do not check if a smaller      
    reporting company)      

    If an emerging growth company, indicate by checkmark if the registrant has not elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨¨

     

     

    CALCULATION OF REGISTRATION FEE

     

     

    Title of Securities to be Registered

     

    Amount to

    be registered (1)

    Proposed maximum

    Offering price

    per share

    Proposed maximum

    aggregate offering

    price

     

    Amount of

    registration fee

    Common stock, $0.001 par value per share, reserved for issuance pursuant to the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan 6,000,000 (2) $15.18(3) $91,080,000.00 $ 9,936.83
    Common stock, $0.001 par value per share, issuable pursuant to outstanding options granted under the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan 1,331,250 (4) $1.26 (5) $1,677,375 $183.00

    (1)In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
    (2)Represents 6,000,000 shares of common stock reserved for issuance pursuant to future awards, and issuable pursuant to outstanding options, granted under the Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (the “2019 Plan”).
    (3)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the registrant’s common stock as reported on The NASDAQ Capital Market on April 8, 2021.
    (4)Represents 1,331,250 shares of common stock subject to outstanding stock options awards under the Anavex Life Sciences Corp. Amended and Restated 2007 Stock Option Plan (the “2007 Plan”).
    (5)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) under the Securities Act of 1933, as amended, and based on the weighted average exercise price of the outstanding options.

     

    2

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

     

    The information required by Item 1 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    The written statement required by Item 2 is included in documents sent or given to participants in the plans covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents have been previously filed by Anavex Life Sciences Corp. (the “Company”) with the Securities and Exchange Commission (the “SEC”) and are hereby incorporated by reference into this registration statement and shall be deemed a part hereof:

     

    (a) The Annual Report of the Company on Form 10-K for the fiscal year ended September 30, 2020, filed with the SEC on December 28, 2020;

     

    (b) The Quarterly Report of the Company on Form 10-Q for the quarter ended December 31, 2020, filed with the SEC on February 16, 2021; and

     

    (d) The description of the Common Stock contained in the registration statement on Form 8-A (Registration No. 001-37606) filed with the SEC on October 23, 2015.

     

    All reports and other documents subsequently filed by the registrant pursuant to sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, except for information furnished under Item 2.02 or 7.01 of Current Report on Form 8-K, or exhibits related thereto, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of the filing of such reports and documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. Any Current Report on Form 8-K that is furnished to the SEC but not filed with the SEC is not deemed incorporated by reference into this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    Not applicable.

     

    3

     

     

    Item 6. Indemnification of Directors and Officers.

     

    Under the Nevada Revised Statutes, director immunity from liability to a company or its stockholders for monetary liabilities applies automatically unless it is specifically limited by a company’s Articles of Incorporation.

    Section 78.7502 of the Nevada Revised Statutes permits a corporation to indemnify a present or former director, officer, employee or agent of the corporation, or any person who is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, except an action by or in the right of the corporation, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or proceeding if such person (1) is not liable pursuant to Section 78.138 of the Nevada Revised Statutes, which sets forth standards for the conduct of directors and officers, or (2) acted in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to a criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

    Section 78.751 of the Nevada Revised Statutes permits any discretionary indemnification under Section 78.7502 of the Nevada Revised Statutes, unless ordered by a court or advanced to a director or officer by the corporation in accordance with the Nevada Revised Statutes, to be made by a corporation only as authorized in each specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances. Such determination must be made (1) by the stockholders, (2) by the board of directors by majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding, (3) if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or (4) if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion. Section 78.751 of the Nevada Revised Statutes provide that the articles of incorporation, bylaws or an agreement made by a corporation may provide that expenses of officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by a corporation as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of a director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that a director or officer is not entitled to be indemnified by the corporation.

    Our Bylaws provide that we will indemnify, to the greatest allowable extent permitted under the Nevada Revised Statutes, directors or officers of the Company for any duties or obligations arising out of any acts or conduct of the officer or director performed for or on behalf of the Company. We will reimburse each such person for all expenses reasonably incurred by him in connection with any such claim or liability, including power to defend such persons from all suits or claims, as provided for under the provisions of the Nevada Revised Statutes. In addition, our Bylaws provide that the board of directors may cause the Company to purchase and maintain insurance on behalf of any person who is or was a director or officer of the Company against any liability asserted against such person and incurred in any such capacity or arising out of such status, whether or not the Corporation would have the power to indemnify such person.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company under Nevada law or otherwise, the Company has been advised that the opinion of the SEC is that such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

     

    At present, there is no pending litigation or proceeding involving any of our directors, officers or employees in which indemnification is sought, nor are we aware of any threatened litigation that may result in claims for indemnification.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    4

     

     

    Item 8. Exhibits.

     

    Exhibit No.   Description of Exhibit
         
    4.1   Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form SB-2 filed on January 13, 2005)
         
    4.2  

    Articles of Incorporation of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed with the SEC on May 9, 2019)

     

    4.3   Bylaws of Anavex Life Sciences Corp. (incorporated by reference to Exhibit 3 to the Company’s Current Report on Form 8-K filed with the SEC on September 28, 2007)
         
    5.1   Opinion of Snell & Wilmer, L.L.P.
         
    23.1   Consent of BDO USA, LLP
         
    23.2   Consent of Snell & Wilmer, L.L.P. (incorporated from Exhibit 5.1)
         
    24.1  

    Power of Attorney (included on signature page hereto)

     

    99.1  

    Anavex Life Sciences Corp. 2019 Omnibus Incentive Plan (incorporated by reference to Annex B to the Company’s Proxy Statement pursuant to Section 14(a) of the Exchange Act filed with the SEC on February 11, 2019)

     

    99.2   Anavex Life Sciences Corp. 2007 Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 28, 2007)
         
    99.3   Anavex Life Sciences Corp. 2007 Amended and Restated Stock Option Plan (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 8, 2011)

      

    5

     

     

    Item 9. Undertakings

     

    1. The undersigned registrant hereby undertakes:

     

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§ 230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    6

     

     SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, as of the 9th day of April 2021.

     

    ANAVEX LIFE SCIENCES CORP.

     

      By: /s/ Christopher Missling, PhD
      Name: Christopher Missling, PhD
      Title: Chief Executive Officer, Principal
        Executive Officer and Chairman of
        the Board of Directors

    7

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of Anavex Life Sciences Corp., do hereby constitute and appoint Christopher Missling, PhD our true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same, with exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite are necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated below:

     

    Signatures   Title(s)   Date
             
    /s/ Christopher Missling, PhD   Chief Executive Officer (Principal Executive Officer)   April 9, 2021
    Christopher Missling, PhD        
             
    /s/ Sandra Boenisch, CPA, CGA   Principal Financial Officer and Treasurer (Principal Accounting   April 9, 2021
    Sandra Boenisch, CPA, CGA   Officer)    
             
    /s/ Athanasios Skarpelos   Director   April 9, 2021
    Athanasios Skarpelos        
             
    /s/ Claus van der Velden, PhD   Director   April 9, 2021
    Claus van der Velden, PhD        
             
    /s/ Elliot Favus, MD   Director   April 9, 2021
    Elliot Favus, MD        
             
    /s/ Steffen Thomas, PhD   Director   April 9, 2021
    Steffen Thomas, PhD        
             
    /s/ Peter Donhauser, D.O.   Director   April 9, 2021
    Peter Donhauser, D.O.        

     

    8

     

    Get the next $AVXL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVXL

    DatePrice TargetRatingAnalyst
    12/6/2022$16.00 → $11.00Overweight → Neutral
    Cantor Fitzgerald
    6/23/2022$40.00Buy
    Berenberg
    2/2/2022$39.00 → $42.00Buy
    HC Wainwright & Co.
    9/23/2021$35.00Buy
    BTIG Research
    6/28/2021$25.00 → $39.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AVXL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anavex Life Sciences Provides Comprehensive Regulatory Update

    Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease Additional data submitted to the U.S. FDA with the objective to discuss potential pathways towards a New Drug Application (NDA) for the treatment of early Alzheimer's disease Additionally, Anavex has engaged in discussions with EU regulators regarding blarcamesine for Parkinson's disease and rare diseases, including Rett syndrome NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's dise

    3/30/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease

    NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults, which had been under review by the European Medicines Agency (EMA). The decision to withdraw the application f

    3/25/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease

    New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI1 control group after 144 weeks (33.1 months) of treatment Oral presentation at the AD/PD™ 2026 Conference Symposium: ‘Advances in AD treatment' highlights the convenience of oral blarcamesine for both patients and families NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurode

    3/23/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anavex Life Sciences Corp.

    SCHEDULE 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

    3/26/26 3:45:48 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

    3/25/26 4:06:00 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ANAVEX LIFE SCIENCES CORP. (0001314052) (Filer)

    2/25/26 6:07:01 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President and CEO Missling Christopher U

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    1/9/26 5:27:25 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by PFO & Treasurer Boenisch Sandra

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    1/9/26 5:26:26 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by PFO & Treasurer Boenisch Sandra

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    10/3/25 8:42:50 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Donhauser Peter D.O. bought $10,319 worth of shares (2,835 units at $3.64), increasing direct ownership by 131% to 5,000 units (SEC Form 4)

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    6/17/24 7:30:10 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Thomas Steffen bought $22,600 worth of shares (5,000 units at $4.52) (SEC Form 4)

    4 - ANAVEX LIFE SCIENCES CORP. (0001314052) (Issuer)

    5/17/24 6:01:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Anavex downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Anavex from Overweight to Neutral and set a new price target of $11.00 from $16.00 previously

    12/6/22 9:27:26 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Berenberg initiated coverage on Anavex with a new price target

    Berenberg initiated coverage of Anavex with a rating of Buy and set a new price target of $40.00

    6/23/22 7:28:39 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on Anavex Life Sciences with a new price target

    HC Wainwright & Co. reiterated coverage of Anavex Life Sciences with a rating of Buy and set a new price target of $42.00 from $39.00 previously

    2/2/22 6:36:27 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Leadership Updates

    Live Leadership Updates

    View All

    Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Dr. Axel Paeger, MD, MBA, MBI to its Board of Directors. "We are delighted to welcome Dr. Paeger to our Board of Directors at Anavex," said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. "Dr. Paeger brings three decades of strong leade

    2/23/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

    NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke is a board-certified neurologist, who brings more than 25 years of extensive experience in developing and delivering innovative medicines in a broad range of CNS diseases, inclu

    1/8/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

    NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the appointment of Professor Dr. Audrey Gabelle, MD, PhD, a specialist of predictive, personalized medicine and digital health in Alzheimer' disease and related disorders, to the Anavex Scientific Advisory Board. Dr. Audrey Gabelle is a Professor of Neurology, MD, PhD, Neurologist and

    4/23/25 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Financials

    Live finance-specific insights

    View All

    Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its first quarter of fiscal 2026. "As we have entered 2026, we continue to progress our innovative clinical pipeline with particular focus on our lead candidate, oral blarcamesine in early Alzheimer's disease

    2/9/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

    NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its first quarter of fiscal 2026 on Monday, February 9, 2026. Management will host a conference call on Monday February 9, at 8:30 am ET to review financial results and discuss recent corporate developments. Following management's remarks, there

    2/3/26 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

    Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its fourth quarter of fiscal 2025. "There are currently an estimated 7.2 million people living with Alzheimer's disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally

    11/25/25 7:30:00 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVXL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

    SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

    2/13/24 4:58:52 PM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

    SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

    1/22/24 11:34:51 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Anavex Life Sciences Corp. (Amendment)

    SC 13G/A - ANAVEX LIFE SCIENCES CORP. (0001314052) (Subject)

    2/9/23 11:07:31 AM ET
    $AVXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care